Physician profile
William Bancroft
NPI 1760046460
$4,888.07
in general payments reported to CMS, 2019-2025
37 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.44 · 2022: $550 · 2023: $1,752 · 2024: $2,093 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,236 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,235.96 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $428.29 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $414.76 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $402.15 | 2022-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $363.65 | 2022-2024 | |
| Abbvie INC. | $323.56 | 2021-2025 | Ubrelvy, Qulipta, Synthroid |
| Bayer Healthcare Pharmaceuticals INC. | $280.68 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $278.77 | 2023-2024 | |
| Glaxosmithkline, LLC. | $252.38 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $221.46 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $215.94 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $208.49 | 2023-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $176.19 | 2024 | Voquezna |
| Averitas Pharma INC. | $175.25 | 2023-2025 | Qutenza |
| Gilead Sciences, INC. | $139.35 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $103.14 | 2022-2024 | Camzyos, Eliquis |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $100.02 | 2023-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.24 | 2023-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $88.17 | 2022-2023 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $87.39 | 2024-2025 | Collagenase Santyl, Regranex, Renasys Touch |
| Corium, LLC | $69.01 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $51.54 | 2021-2024 | Trintellix |
| Amarin Pharma, INC. | $50.19 | 2022-2023 | |
| Urgo Medical North America, LLC | $42.23 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4, Urgok2 |
| Janssen Pharmaceuticals, INC | $37.83 | 2022-2024 | Xarelto |
| Mimedx Group, INC. | $32.74 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.92 | 2023-2024 | Jardiance, Tradjenta |
| Kerecis Limited | $26.21 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Organogenesis INC. | $25.56 | 2025 | Affinity |
| Ucb, INC. | $24.17 | 2021 | |
| Radius Health, INC. | $20.60 | 2025 | Tymlos |
| Neurocrine Biosciences, INC. | $19.53 | 2025 | |
| Ossur Americas, INC. | $18.14 | 2024 | |
| Eisai INC. | $17.69 | 2024 | |
| Horizon Therapeutics Plc | $17.61 | 2022 | |
| Exact Sciences Corporation | $17.53 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $13.42 | 2024 | Injectafer |
| Beta Bionics, INC. | $13.27 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bancroft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.